Kisspeptin-10 is the ten-amino-acid working core of kisspeptin, the signal sitting at the very top of the reproductive hormone chain.
What matters first
Why people look it up
It is sold for libido, for fertility, and for raising testosterone.
What the evidence shows
The human work is physiology research in groups of four to six people, run to map the circuit rather than to treat anyone. Given into a vein it lifted luteinising hormone in men within half an hour. Given under the skin — the route these vials are sold for — it moved neither hormone in the women studied.
Dose status
Kisspeptin-10 is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.
Kisspeptin-10 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.
Evidence snapshot
Foreign approval or limited human data
The fastest way to see what kind of evidence this page is built on.
Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study3 reported dose rows
Safety evidence
No listed safety findingsNo reactions reported here
Kisspeptin-10 at a glance: foreign approval or limited human data, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer·Reviewed 2026-08-12·open the primary sources
What is known about Kisspeptin-10
Kisspeptin-10 is the ten-amino-acid working core of kisspeptin. It starts the hormone signal that drives the reproductive system. University studies gave it to healthy volunteers to map that circuit, not to treat a condition. A dose into a vein raised luteinizing hormone in men within 30 minutes. The same peptide injected under the skin changed neither measured hormone in women studied mid-cycle.
Kisspeptin-10 research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
Topic
Value
Strongest source
limited human data
FDA approval
Not FDA-approved
Studied dosing
41.7 mcg once per kilogram of body weight (published as 32 nmol/kg; the largest under-the-skin dose in the study did not raise either measured hormone in women sampled mid-cycle)— from clinical trials
Studied dosing
0.01–3 mcg once per kilogram of body weight (in healthy men, luteinizing hormone peaked at 1 mcg/kg; 3 mcg/kg produced a smaller response)— from clinical trials
Studied dosing
1.5–4 mcg per kilogram per hour, infused for up to 22.5 hours in healthy men (the lower rate raised LH pulse frequency; the higher rate raised testosterone)— from clinical trials
Typical vials
5 mg · 10 mg
Every row links back to a source listed below. These facts are for reference, not a personal recommendation.
What the evidence for Kisspeptin-10 is
People have received this compound in a documented setting, or it has approval outside the United States. The available human evidence is still too limited to show a clear dose-and-result pattern for US use.
limited human data
What it establishes
It shows that people have received it and that some human information exists.
What it does not establish
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
Check the country, study size and reason it was used. Do not treat limited human data as an FDA-approved schedule.
Where Kisspeptin-10 is in clinical trials
5 registered studies; the program has reached phase 3. Nothing is currently open or enrolling.
Phase 3Completed
Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men
Quaid-e-Azam University · Sterility, Reproductive · 15 participants · started August 2014
Quaid-e-Azam University · Kisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men · 14 participants · started October 2013
A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.
University studies have given kisspeptin-10 to people under ethics review.
Their doses were scaled to body weight and used to map hormones, not to set a treatment dose. FDA placed it in category 2 of its interim 503A compounding policy on September 29, 2023. It is not on the withdrawn list.
An FDA committee reviewed it for low hormone function in men on October 29, 2024, but a review is not an approval.
Every human study dose was scaled to body weight. A flat number without a body weight is not the same dose.
The largest under-the-skin dose did not change LH or FSH in women sampled mid-cycle.
The response varied by sex and menstrual-cycle phase.
In one dose-ranging arm, 3 mcg/kg produced a smaller luteinizing-hormone response than 1 mcg/kg.
These studies mapped hormone signals; they did not establish a treatment dose.
Study groups held four to six people, too few to detect uncommon harm.
The peptide starts a chain that affects several reproductive hormones.
An FDA committee reviewed it for low hormone function in men on October 29, 2024. A review is not an approval.
FDA placed it in category 2 of its interim 503A policy on September 29, 2023. FDA cited immune-reaction risk, impurities, and limited safety data.
Material sold online is not the pharmaceutical-grade product used in those studies.
Questions about Kisspeptin-10
Is Kisspeptin-10 FDA-approved?
No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.
How is Kisspeptin-10 taken?
Trials study it both by injection under the skin and by drip or injection into a vein. The table above keeps each route and schedule separate.
How does Kisspeptin-10 differ from the other compounds in this class?
Kisspeptin-10 has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.
What is not known about Kisspeptin-10?
It does not prove that the same dose is appropriate in the United States or that uncommon and long-term risks are known.
2primary sources, each with the day we read it — open the documents used on this page
